Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation

Bosi, Alberto; Laszlò, Daniele; Labopin, Myriam; Reffeirs, Josy; Michallet, Mauricette; Gluckman, Éliane; Alessandrino, Paolo Emilio; Locatelli, Franco; Vernant, Jean Paul; Sierra, Jorge; Jouet, Jean Pierre; Frassoni, Francesco

doi:10.1200/jco.2001.19.16.3675

Cited by 168 publications

(240 citation statements)

References 20 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…Severe GVHD resulted in a high NRM for patients who underwent allo-SCT twice. This result differs from those of previous studies on adult leukemia 3 and might have arisen from the fact that most of the patients in the previous studies had AML, which is known to be relatively sensitive to GVL effects. …”

Section: Discussioncontrasting

confidence: 56%

“…In these reports, the OS of second SCT was reported to be around 30%. 3,9 However, the number of pediatric patients included in these previous studies was small, thus the role of second SCT remains unclear.…”

Section: Discussionmentioning

confidence: 99%

“…2,3,5,11 These studies demonstrated that the duration of remission after the first SCT, conditioning regimens including TBI, and acute GVHD were prognostic factors, although most of these studies included both ALL and AML patients. A few reports included pediatric patients, and these studies showed that the outcomes and prognostic factors of second SCT were similar to those for adults.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Second allogeneic hematopoietic SCT for relapsed ALL in children

Kato

Hirono

Okamoto

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4 ± 3.7%, the cumulative incidence of relapse was 44.1±4.0% and non-relapse mortality was 18.8±3.5%. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P ¼ 0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT. Keywords: second transplantation; relapse; ALL; children INTRODUCTION SCT is the most effective treatment for high-risk and refractory leukemia, but relapse is still a major event of allo-SCT. It is generally accepted that a second SCT is the only potentially curative approach for patients who relapse after allo-SCT, but only some patients are eligible for a second SCT because of the high mortality and morbidity associated with repeated allo-SCT. In addition, high relapse rates occur because of the resistance of leukemic cells that have not been eliminated by the first SCT. Some previous studies have examined the role of second SCT, 1 --10 but because of the small number of patients in these studies, the efficacy and safety of second allo-SCT for pediatric ALL patients that have relapsed after SCT remains unclear.In this study, to investigate the prognostic factors of second SCT and identify subgroups for whom second SCT is effective, we performed a retrospective analysis of 171 patients who received a second SCT for relapsed ALL after allo-SCT.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Second allogeneic hematopoietic SCT for relapsed ALL in children

Kato

Hirono

Okamoto

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…These patients pose a special therapeutic challenge, since they are especially prone to TRM due to heavy pretreatment, while also carrying a very high risk of relapse. [5][6][7][8] We tried to address both problems by developing a novel RIC protocol with fludarabine and thiotepa aiming to combine efficacy with low organ toxicity. 3 Thiotepa was chosen because it is a welltolerated alkylator with potent antileukaemic as well as stem-cell toxic activity, [17][18][19] whereas fludarabine is as immunosuppressive as CY, but less toxic and enhances alkylator-induced damage by inhibiting DNA repair.…”

Section: Discussionmentioning

confidence: 99%

“…3,4 Second, despite high TRM and GVHD rates, relapse remains the main cause of death in this very high-risk patient population. [5][6][7][8] The concept of allo-SCT with reduced-intensity conditioning (RIC) is based on the notion that the GVL contributes significantly to the curative potential. This permits dose reductions of preparative chemotherapy or radiation with a lower overall toxicity.…”

Section: Introductionmentioning

confidence: 99%

Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML

Christopoulos

Schmoor

Waterhouse

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

A second allograft was offered to 58 relapsed AML patients after conditioning with fludarabine 90-150 mg/m 2 and thiotepa 15 mg/kg, in most cases with active disease. Median age was 53 years (range 23-69), median time to relapse after the first allo-SCT was 326 (47-2189) days and median follow-up was 6.7 years. GVHD prophylaxis consisted mainly of CsA and alemtuzumab. Response rates at 1 month were CR in 50 and persistent disease in 3/53 evaluable patients. At 3 years, the relapse incidence (95% confidence interval) was 56 (45-71)%, the TRM 31 (21-46)%, the OS rate was 18 (9-29)% and the EFS rate was 13 (5-23)%. OS improved with younger patient age, longer relapse-free interval after the first allo-SCT and the development of chronic GVHD. Patients p65 years old who relapsed 412 months after the first allograft (n ¼ 20) had a 3-year OS rate of 41 (19-62)%. Conventional cytogenetics and FLT3 mutation status did not affect outcome. Our regimen is feasible and provides at least for a subgroup of patients with AML recurrence after allo-SCT a reasonable therapeutic option in an otherwise fatal situation. Further modifications and a better understanding of the underlying biology could help lower the risk of relapse. INTRODUCTIONFor patients with AML, relapsing after allo-SCT prognosis is very poor. A second allograft is currently the only therapeutic approach capable of inducing long-term remissions in patients who cannot be salvaged with DLI. 1,2 This approach has, however, two main limitations. First, many of these patients cannot tolerate a second allo-SCT because of accumulated organ toxicities and opportunistic infections, which increase the risk for TRM and severe GVHD. 3,4 Second, despite high TRM and GVHD rates, relapse remains the main cause of death in this very high-risk patient population. [5][6][7][8] The concept of allo-SCT with reduced-intensity conditioning (RIC) is based on the notion that the GVL contributes significantly to the curative potential. This permits dose reductions of preparative chemotherapy or radiation with a lower overall toxicity. 9 In 2008, we reported the results of a phase II RIC trial using fludarabine 5 Â 30 mg/m 2 and thiotepa 3 Â 5 mg/kg in patients with recurrent or persistent haematological malignancies after a previous auto-or allo-SCT. 3 In this series, a TRM (95% confidence interval) of 29 (14-44)% at 2 years despite heavy pretreatment demonstrated the feasibility of our regimen, but the low number of patients in each diagnostic subgroup and the relatively short follow-up precluded a thorough evaluation of efficacy.Here we analyse the long-term outcome of a larger, homogeneous patient cohort with AML at relapse after first allo-SCT treated in a similar manner.

show abstract

Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia

Appelbaum

2015

Thomas’ Hematopoietic Cell Transplantation

View full text Add to dashboard Cite

Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation

Cited by 168 publications

References 20 publications

Second allogeneic hematopoietic SCT for relapsed ALL in children

Second allogeneic hematopoietic SCT for relapsed ALL in children

Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML

Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia

Contact Info

Product

Resources

About